170 related articles for article (PubMed ID: 38228583)
1. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract][Full Text] [Related]
2. A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth.
Li SP; Ou L; Zhang Y; Shen FR; Chen YG
Cell Death Dis; 2023 Feb; 14(2):152. PubMed ID: 36823110
[TBL] [Abstract][Full Text] [Related]
3. Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer.
Li X; Yao L; Wang T; Gu X; Wu Y; Jiang T
Cell Death Dis; 2023 Oct; 14(10):665. PubMed ID: 37816734
[TBL] [Abstract][Full Text] [Related]
4. The mitochondrial RNA polymerase POLRMT promotes skin squamous cell carcinoma cell growth.
Wang Y; Ou L; Li X; Zheng T; Zhu WP; Li P; Wu L; Zhao T
Cell Death Discov; 2022 Aug; 8(1):347. PubMed ID: 35922422
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed Gαi1 exerts pro-tumorigenic activity in nasopharyngeal carcinoma.
Yin DP; Zhang H; Teng H; Zhang D; Chen P; Xie L; Liu JS
Cell Death Dis; 2023 Dec; 14(12):792. PubMed ID: 38049415
[TBL] [Abstract][Full Text] [Related]
6. Identification of mitochondrial RNA polymerase as a potential therapeutic target of osteosarcoma.
Han QC; Zhang XY; Yan PH; Chen SF; Liu FF; Zhu YR; Tian Q
Cell Death Discov; 2021 Dec; 7(1):393. PubMed ID: 34907167
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
8. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
10. ADCK1 is a potential therapeutic target of osteosarcoma.
Zhuo BB; Zhu LQ; Yao C; Wang XH; Li SX; Wang R; Li Y; Ling ZY
Cell Death Dis; 2022 Nov; 13(11):954. PubMed ID: 36371387
[TBL] [Abstract][Full Text] [Related]
11. HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth.
Han Q; Yan P; Song R; Liu F; Tian Q
Cell Death Dis; 2023 Jul; 14(7):398. PubMed ID: 37407582
[TBL] [Abstract][Full Text] [Related]
12. The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth.
Zhou T; Sang YH; Cai S; Xu C; Shi MH
Cell Death Dis; 2021 Jul; 12(8):751. PubMed ID: 34326320
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
14. Identification of Gαi3 as a promising target for osteosarcoma treatment.
Bian ZJ; Shan HJ; Zhu YR; Shi C; Chen MB; Huang YM; Wang XD; Zhou XZ; Cao C
Int J Biol Sci; 2022; 18(4):1508-1520. PubMed ID: 35280670
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
16. A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.
Zhang L; Shi X; Zhang L; Mi Y; Zuo L; Gao S
Cell Death Dis; 2024 Mar; 15(3):204. PubMed ID: 38467612
[TBL] [Abstract][Full Text] [Related]
17. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met/Akt/mTOR pathway in human osteosarcoma cells.
Mei L; Sang W; Cui K; Zhang Y; Chen F; Li X
Cancer Sci; 2019 Feb; 110(2):582-595. PubMed ID: 30520540
[TBL] [Abstract][Full Text] [Related]
18. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
20. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway.
Wei Z; Xia K; Zheng D; Gong C; Guo W
Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
